-

04:47:21 PM

KDNY Stock News

KDNY - Chinook Therapeutics Inc

05/12/22 4:00 PM

Nasdaq : KDNY

earnings

Chinook Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results

Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today provided a business update and reported financial results for the first

RHEA-AI

neutral

05/02/22 10:25 AM

Nasdaq : KDNY

conferences

Chinook Therapeutics Announces Upcoming Data Presentations and Investor Conference Call at the 59th European Renal Association (ERA) Congress

Data on atrasentan to be presented in an oral presentation from the IgA nephropathy (IgAN) patient cohort of the phase 2 AFFINITY basket trial Updated data to be presented from Cohort 1 of Part 3 of the ongoing phase 1/2 study of BION-1301 in patients with IgAN Additional abstracts to be presented

RHEA-AI

neutral

04/25/22 4:05 PM

Nasdaq : KDNY

conferences

Chinook Therapeutics to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference

Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that Chinook management is scheduled to present and

RHEA-AI

neutral

04/12/22 8:00 AM

Nasdaq : KDNY

clinical trial

Chinook Therapeutics Announces Initiation of Phase 1 Healthy Volunteer Trial of CHK-336, a First-in-Class LDHA Inhibitor to Treat Hyperoxalurias

Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that dosing has been initiated in a phase 1 clinical trial

RHEA-AI

neutral

04/05/22 4:05 PM

Nasdaq : KDNY

conferences

Chinook Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference

Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that Eric Dobmeier, president and chief executive officer of

RHEA-AI

neutral

04/05/22 8:00 AM

Nasdaq : KDNY

Chinook Therapeutics, IgA Nephropathy Foundation and Komodo Health Collaborate to Provide Nephrologists with Support and Information to Help Reduce Barriers to Diagnosis and Care

Chinook Therapeutics, Inc. (Nasdaq: KDNY), the IgA Nephropathy Foundation and Komodo Health today announced an outreach initiative leveraging data and technology to drive awareness of Immunoglobulin A (IgA) nephropathy and engage key medical providers

RHEA-AI

neutral

03/21/22 8:15 AM

Nasdaq : KDNY

management

Chinook Therapeutics Announces Appointment of Dr. Mahesh Krishnan to its Board of Directors

Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced the appointment of Mahesh Krishnan, M.D., M.P.H., M.B.A., FASN

RHEA-AI

very positive

03/17/22 4:00 PM

Nasdaq : KDNY

earnings

Chinook Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results

Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today provided a business update and reported financial results for the fourth

RHEA-AI

positive

03/08/22 4:05 PM

Nasdaq : KDNY

conferences

Chinook Therapeutics to Present at Oppenheimer’s 32nd Annual Healthcare Conference

Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that Chinook management is scheduled to participate in a

RHEA-AI

neutral

02/22/22 8:15 AM

Nasdaq : KDNY

conferences

Chinook Therapeutics Announces Upcoming Presentations at 4th Annual Chronic Kidney Disease Drug Development Summit

Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced upcoming presentations at the 4 th Annual Chronic Kidney

RHEA-AI

neutral

Prev 1 2 3 4 5 6 7 Next

KDNY Data

IndustryPharmaceutical Preparation Manufacturing
Website/www.chinooktx.com
CeoStephen Isaacs
Security nameChinook Therapeutics Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees105
Tags
- Health Technology
- Biotechnology
- Commercial Services
- Miscellaneous Commercial Services
- Pharmaceuticals: Major
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Address740 Heinz Ave
StateCalifornia
CityBerkeley
Zip94710-2748
CountryUS
Phone15108484400

About Chinook Therapeutics Inc

Chinook Therapeutics, Inc. is a clinical-stage biotechnology company developing precision medicines for kidney diseases. Chinook's product candidates are being investigated in rare, severe chronic kidney disorders with opportunities for well-defined clinical pathways. Chinook's lead program is atrasentan, an investigational phase 3 endothelin receptor antagonist for the treatment of IgA nephropathy and other primary glomerular diseases. BION-1301, an investigational anti-APRIL monoclonal antibody is being evaluated in a phase 1b trial for IgA nephropathy. In addition, Chinook is advancing CHK-336, an investigational oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare, severe chronic kidney diseases, including polycystic kidney disease. Chinook is building its pipeline by leveraging insights in kidney single cell RNA sequencing, human-derived organoids and new translational models, to discover and develop therapeutics with differentiating mechanisms of action against key kidney disease pathways.